Boston, MA 06/10/2013 (wallstreetpr) – The shares of Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had declined by 9.94 percent to close at $3.26 per share for the end of last trading session on Friday. The shares of the company had been trading in the range of $3.25 to $3.60 per share during the day. This recent decline in the share prices had further plunged Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) to new levels of 52 week low prices at $3.25 per share, while the 52 week high price level of the company is at $38.60 per share.
Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) is primarily engaged in the development and commercialization of biotechnology products used for delivering oxygen to the issue. The company had till now developed a wide range of perfluorcarbon products which are used as oxygen carriers in personal care, topical wound healing and other topical indications. Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had recently announced a reverse stock split based on the ratio of 20 to one for the shareholders as on record of April 26, 2013.
The reverse stock split was approved at the special shareholders meeting of the company and it came to effect on May 10, 2013. Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had recently appointed Dr. Charles L. Pamplin III as the Chief Medical Officer to take care of the strategic clinical development plan of the company.
Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had recently been witnessing heavy trading volumes at nearly double the average volume. The company witnessed the trade of 14,360 shares on the last trading session of Friday, while the average trading volume of the company is at 8,090 shares per day. The company presently has 2.66 million shares outstanding in the market with an institutional ownership in the company at 5 percent of its holdings.
